Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Breast Cancer Congress 2023

Omitting anthracyclines for the adjuvant treatment of early breast cancer: The case of TNBC

Clinician’s perspective

Date

13 May 2023

Session

Omitting anthracyclines for the adjuvant treatment of early breast cancer: The case of TNBC

Topics

Tumour Site

Breast Cancer

Presenters

Peter A. Fasching

Authors

P.A. Fasching

Author affiliations

  • Universitätsklinikum Erlangen, Erlangen/DE

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Introduction to the topic

Presenter: Peter A. Fasching

Session: Omitting anthracyclines for the adjuvant treatment of early breast cancer: The case of TNBC

Resources:

Webcast

Q&A and discussion

Presenter: To be Announced

Session: Omitting anthracyclines for the adjuvant treatment of early breast cancer: The case of TNBC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.